1. Home
  2. SOWG vs BYSI Comparison

SOWG vs BYSI Comparison

Compare SOWG & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sow Good Inc.

SOWG

Sow Good Inc.

HOLD

Current Price

$2.99

Market Cap

63.4M

ML Signal

HOLD

Logo BeyondSpring Inc.

BYSI

BeyondSpring Inc.

HOLD

Current Price

$1.15

Market Cap

58.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SOWG
BYSI
Founded
2010
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
63.4M
58.4M
IPO Year
2011
2016

Fundamental Metrics

Financial Performance
Metric
SOWG
BYSI
Price
$2.99
$1.15
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
17.2K
23.1K
Earning Date
05-15-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.10
$0.99
52 Week High
$4.45
$2.44

Technical Indicators

Market Signals
Indicator
SOWG
BYSI
Relative Strength Index (RSI) 44.31 36.90
Support Level $0.38 $1.18
Resistance Level $4.43 $1.60
Average True Range (ATR) 0.27 0.09
MACD -0.12 -0.00
Stochastic Oscillator 23.04 42.66

Price Performance

Historical Comparison
SOWG
BYSI

About SOWG Sow Good Inc.

Sow Good Inc is engaged in manufacturing and marketing freeze-dried fruits, vegetables, snacks, smoothies, and soups. The company also sells gluten-free products under the Sow Good brand. The company is developing a freeze-dried candy market and snack manufacturing to provide consumers with flavorful freeze-dried treats. The company operates in one reportable segment, reflecting its capital-light business model under which it earns proceeds from the sale of freeze-dried candy products.

About BYSI BeyondSpring Inc.

BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.

Share on Social Networks: